Q-omics provides the consensus-scored MYADM profile across patient tissues and cancer cell-line models. MYADM expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MYADM is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, MYADM protein abundance shows 22,711 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BLCA, and LSCC as cancer lineages where MYADM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYADM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYADM survival associations across molecular data types. MYADM RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYADM RNA expression–survival associations across cancer types. High MYADM expression shows unfavorable associations in ACC, MESO, LUSC, LGG, BLCA and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MYADM RNA expression.
This table summarizes MYADM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MYADM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYADM shows lower tumor expression in BLCA, KICH, UCEC, LUAD and LUSC and higher tumor expression in KIRC. The BLCA box plot shows higher MYADM RNA expression in normal versus tumor tissue (log2 FC = −3.061, t-test p < 0.001).
This table shows molecular features associated with MYADM in patient tissues and cancer cell lines. In patient samples, MYADM shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYADM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
